A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.

Key facts

Study ID
NCT07013487
Run by
Merck Sharp & Dohme LLC
People needed
12000
Starts
2025-06-11
Expected to finish
2031-10-24
Last updated by the study team
2026-07-10

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.